They Call it the Rabbit Hole - Episode #6 · Peptides: Out of the Shadows

Adam Serge

May 26 • The Rabbit Hole

They Call it the Rabbit Hole - Episode #6

A while back we had a discussion around where peptide delivery methods may be heading over the next several years:

• capsules

• tablets

• sublingual delivery

• liposomal systems

• nasal sprays

• transdermal options

• and lower-friction administration overall.

One of the more interesting parts of this entire discussion is that oral tablets and capsules became the “normal” option long before most people ever started questioning whether they were actually the most efficient delivery method biologically.

But honestly, that “normal” likely evolved for a lot of practical reasons:• easier mass production• longer shelf stability• easier transportation and storage• lower manufacturing costs• easier patient compliance• and much broader consumer acceptance.

And realistically, a huge percentage of the population simply does not want to deal with injections at all.

For many people, needles create a very real psychological barrier. Some people are uncomfortable with them. Some are intimidated by them. Some outright hate them.

So even if an injectable version could theoretically improve delivery or absorption, many individuals would still choose the oral option simply because the mental image of self-injection is a complete non-starter.

A capsule or tablet simply feels easier, safer, more familiar, and psychologically more manageable for most people.

At the same time, oral compounds still have to survive:

• stomach acid

• digestion

• intestinal absorption

• and liver processing

before the body can actually utilize them systemically.

That does not automatically make oral delivery “bad.”

But it does raise reasonable questions about how much is truly being absorbed and utilized compared to alternative delivery methods.

The problem is we are probably never going to see massive human clinical trials comparing oral versus injectable delivery for most peptides, nutraceuticals, amino acids, or connective tissue support compounds.

Not necessarily because the concepts lack scientific merit…but because the economics often do not make sense.

Large human trials are incredibly expensive, and many of these compounds simply do not have the financial upside necessary to justify billion-dollar research pipelines.

So, the absence of large-scale human data does not automatically prove oral delivery is biologically superior.

In many cases, it is simply the most practical and commercially scalable option for the largest number of people.

0 comments

They Call it the Rabbit Hole - Episode #6